Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma.[3][4]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD125 |
Clinical data | |
Pronunciation | ben" ra liz' ue mab |
Trade names | Fasenra |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618002 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6492H10060N1724O2028S42 |
Molar mass | 146056.45 g·mol−1 |
(what is this?) (verify) |
Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[5][6] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma.[7] It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.[8]
Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.[9]